Lowering Homocysteine in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death: The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial | Cerebrovascular Disease | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
Carson NA, Neill DW. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland.  Arch Dis Child.1962;37:505-513.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14018926&dopt=AbstractGoogle Scholar
2.
Gerritsen T, Vaughn JG, Waisman HA. The identification of homocystine in the urine.  Biochem Biophys Res Commun.1962;9:493-496.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=13960563&dopt=AbstractGoogle Scholar
3.
McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis.  Am J Pathol.1969;56:111-128.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5792556&dopt=AbstractGoogle Scholar
4.
Boers GH, Smals AG, Trijbels FJ.  et al.  Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease.  N Engl J Med.1985;313:709-715.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4033695&dopt=AbstractGoogle Scholar
5.
Clarke R, Daly L, Robinson K.  et al.  Hyperhomocysteinemia: an independent risk factor for vascular disease.  N Engl J Med.1991;324:1149-1155.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2011158&dopt=AbstractGoogle Scholar
6.
Brattstrom LE, Hardebo JE, Hultberg BL. Moderate homocysteinemia—a possible risk factor for arteriosclerotic cerebrovascular disease.  Stroke.1984;15:1012-1016.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6506111&dopt=AbstractGoogle Scholar
7.
Brattstrom L, Lindgren A, Israelsson B.  et al.  Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors.  Eur J Clin Invest.1992;22:214-221.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1582447&dopt=AbstractGoogle Scholar
8.
Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke.  Stroke.1990;21:572-576.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2326839&dopt=AbstractGoogle Scholar
9.
Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men.  Lancet.1995;346:1395-1398.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7475822&dopt=AbstractGoogle Scholar
10.
Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke.  Stroke.1994;25:1924-1930.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8091435&dopt=AbstractGoogle Scholar
11.
Yoo JH, Chung CS, Kang SS. Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis.  Stroke.1998;29:2478-2483.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9836754&dopt=AbstractGoogle Scholar
12.
Graham IM, Daly LE, Refsum HM.  et al.  Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project.  JAMA.1997;277:1775-1781.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9178790&dopt=AbstractGoogle Scholar
13.
Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease.  N Engl J Med.1997;337:230-236.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9227928&dopt=AbstractGoogle Scholar
14.
Eikelboom JW, Lonn E, Genest Jr J, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence.  Ann Intern Med.1999;131:363-375.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10475890&dopt=AbstractGoogle Scholar
15.
Homocysteine Studies Collaboration.  Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.  JAMA.2002;288:2015-2022.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12387654&dopt=AbstractGoogle Scholar
16.
Boysen G, Brander T, Christensen H, Gideon R, Truelsen T. Homocysteine and risk of recurrent stroke.  Stroke.2003;34:1258-1261.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12702838&dopt=AbstractGoogle Scholar
17.
den Heijer M, Koster T, Blom HJ.  et al.  Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.  N Engl J Med.1996;334:759-762.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8592549&dopt=AbstractGoogle Scholar
18.
Stamler JS, Slivka A. Biological chemistry of thiols in the vasculature and in vascular-related disease.  Nutr Rev.1996;54:1-30.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8919695&dopt=AbstractGoogle Scholar
19.
Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy.  Circulation.1999;99:1156-1160.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10069782&dopt=AbstractGoogle Scholar
20.
van den Berg M, Boers GH, Franken DG.  et al.  Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease.  Eur J Clin Invest.1995;25:176-181.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7781664&dopt=AbstractGoogle Scholar
21.
Leerink CB, van Ham AD, Heeres A, Duif PF, Bouma BN, van Rijn HJ. Sulfhydryl compounds influence immunoreactivity, structure and functional aspects of lipoprotein(a).  Thromb Res.1994;74:219-232.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8042190&dopt=AbstractGoogle Scholar
22.
Brattstrom L. Vitamins as homocysteine-lowering agents.  J Nutr.1996;126(suppl):1276S-1280S.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8642470&dopt=AbstractGoogle Scholar
23.
Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia.  Lancet.1998;351:263.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9457098&dopt=AbstractGoogle Scholar
24.
Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial.  JAMA.2002;288:973-979.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12190367&dopt=AbstractGoogle Scholar
25.
Spence JD, Howard VJ, Chambless LE.  et al.  Vitamin Intervention for Stroke Prevention (VISP) trial: rationale and design.  Neuroepidemiology.2001;20:16-25.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11174041&dopt=AbstractGoogle Scholar
26.
Howard VJ, Sides EG, Newman GC.  et al. for the Stability of Plasma Homocyst(e)ine in Acute Stroke Patients (SHASP) Study Investigators.  Changes in plasma homocyst(e)ine in the acute phase after stroke.  Stroke.2002;33:473-478.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11823655&dopt=AbstractGoogle Scholar
27.
Mudd SH, Levy HL. Plasma homocyst(e)ine or homocysteine?  N Engl J Med.1995;333:325.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7596391&dopt=AbstractGoogle Scholar
28.
D'Olhaberriague L, Litvan I, Mitsias P.  et al.  A reappraisal of reliability and validity studies in stroke.  Stroke.1996;27:2331-2336.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8969803&dopt=AbstractGoogle Scholar
29.
Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician.  J Psychiatr Res.1975;12:189-198.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1202204&dopt=AbstractGoogle Scholar
30.
Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys.  Bull World Health Organ.1962;27:645-658.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=13974778&dopt=AbstractGoogle Scholar
31.
Smolin LA, Schneider JA. Measurement of total plasma cysteamine using high-performance liquid chromatography with electrochemical detection.  Anal Biochem.1988;168:374-379.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3364734&dopt=AbstractGoogle Scholar
32.
Malinow MR, Kang SS, Taylor LM.  et al.  Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease.  Circulation.1989;79:1180-1188.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2785871&dopt=AbstractGoogle Scholar
33.
Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson D, Upson B. Homocyst(e)ine in daily practice: levels in coronary artery disease.  Coron Artery Dis.1990;1:215-220.Google Scholar
34.
Piantadosi S. Clinical Trials: A Methodologic PerspectiveNew York, NY: John Wiley & Sons; 1977.
35.
Food and Nutrition Board, Institute of Medicine.  Dietary Reference Intakes for Thiamin, Riboflavin Niacin, Vitamin B6, Folate, Vitamin B12, Panothenic Acid, Biotin, and CholineWashington, DC: National Academy Press; 1988.
36.
 Hospital & Payer International Classification of Diseases, Ninth Revision, Clinical Modification. 5th ed. Salt Lake City, Utah: Medicode Publications; 1999.
37.
Halperin M, Lan KK, Ware JH, Johnson NJ, DeMets DL. An aid to data monitoring in long-term clinical trials.  Control Clin Trials.1982;3:311-323.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7160189&dopt=AbstractGoogle Scholar
38.
Lan KK, Wittes J. The B-value: a tool for monitoring data.  Biometrics.1988;44:579-585.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3390511&dopt=AbstractGoogle Scholar
39.
Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time DataNew York, NY: John Wiley & Sons; 1980.
40.
Nygård O, Nordehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease.N Engl J Med. 1997;337:230-236.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9227928&dopt=Abstract
41.
Graham IM, Daly L, Refsum H.  et al.  Plasma homocysteine as a risk factor for vascular disease.  JAMA.1997;277:1775-1781.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9178790&dopt=AbstractGoogle Scholar
42.
Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis.  BMJ.2002;325:1202.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12446535&dopt=AbstractGoogle Scholar
43.
Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations.  N Engl J Med.1999;340:1449-1454.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10320382&dopt=AbstractGoogle Scholar
44.
Stampfer MJ, Malinow MR, Willet WC.  et al.  A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians.  JAMA.1992;268:877-881.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1640615&dopt=AbstractGoogle Scholar
45.
Baker F, Picton D, Blackwood S.  et al.  Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial.  Circulation.2002;106(suppl):II741S.Google Scholar
Original Contribution
February 4, 2004

Lowering Homocysteine in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death: The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial

Author Affiliations

Author Affiliations: Stroke Research Center, Department of Neurology, Wake Forest University School of Medicine, Winston-Salem, NC (Dr Toole and Ms Sides); Laboratory of Cardiovascular Disease, Oregon National Primate Research Center, Beaverton (Dr Malinow); Department of Biostatistics, Collaborative Studies Coordinating Center, University of North Carolina at Chapel Hill (Drs Chambless and Wang); Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, London, Ontario (Dr Spence); Stroke Program/Sanders-Brown Center on Aging, University of Kentucky, Lexington (Dr Pettigrew); Department of Epidemiology and International Health, University of Alabama, Birmingham (Ms Howard); and Department of Epidemiology, Harvard School of Public Health, Boston, Mass (Dr Stampfer).

JAMA. 2004;291(5):565-575. doi:10.1001/jama.291.5.565
Abstract

Context In observational studies, elevated plasma total homocysteine levels have been positively associated with ischemic stroke risk. However the utility of homocysteine-lowering therapy to reduce that risk has not been confirmed by randomized trials.

Objective To determine whether high doses of folic acid, pyridoxine (vitamin B6), and cobalamin (vitamin B12), given to lower total homocysteine levels, reduce the risk of recurrent stroke over a 2-year period compared with low doses of these vitamins.

Design Double-blind randomized controlled trial (September 1996–May 2003).

Setting and Participants 3680 adults with nondisabling cerebral infarction at 56 university-affiliated hospitals, community hospitals, private neurology practices, and Veterans Affairs medical centers across the United States, Canada, and Scotland.

Interventions All participants received best medical and surgical care plus a daily multivitamin containing the US Food and Drug Administration's reference daily intakes of other vitamins; patients were randomly assigned to receive once-daily doses of the high-dose formulation (n = 1827), containing 25 mg of pyridoxine, 0.4 mg of cobalamin, and 2.5 mg of folic acid; or the low-dose formulation (n = 1853), containing 200 µg of pyridoxine, 6 µg of cobalamin,and 20 µg of folic acid.

Main Outcome Measures Recurrent cerebral infarction (primary outcome); coronary heart disease (CHD) events and death (secondary outcomes).

Results Mean reduction of total homocysteine was 2 µmol/L greater in the high-dose group than in the low-dose group, but there was no treatment effect on any end point. The unadjusted risk ratio for any stroke, CHD event, or death was 1.0 (95% confidence interval [CI], 0.8-1.1), with chances of an event within 2 years of 18.0% in the high-dose group and 18.6% in the low-dose group. The risk of ischemic stroke within 2 years was 9.2% for the high-dose and 8.8% for the low-dose groups (risk ratio, 1.0; 95% CI, 0.8-1.3) (P = .80 by log-rank test of the primary hypothesis of difference in ischemic stroke between treatment groups). There was a persistent and graded association between baseline total homocysteine level and outcomes. A 3-µmol/L lower total homocysteine level was associated with a 10% lower risk of stroke (P = .05), a 26% lower risk of CHD events (P<.001), and a 16% lower risk of death (P = .001) in the low-dose group and a nonsignificantly lower risk in the high-dose group by 2% for stroke, 7% for CHD events, and 7% for death.

Conclusions In this trial, moderate reduction of total homocysteine after nondisabling cerebral infarction had no effect on vascular outcomes during the 2 years of follow-up. However, the consistent findings of an association of total homocysteine with vascular risk suggests that further exploration of the hypothesis is warranted and longer trials in different populations with elevated total homocysteine may be necessary.

×